CLINICAL TRIALS PROFILE FOR DIDANOSINE

505(b)(2) Clinical Trials for DIDANOSINE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00002234 ↗	Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients	Completed	Bristol-Myers Squibb	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.
New Combination	NCT00002234 ↗	Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients	Completed	Dupont Applied Biosciences	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.
New Combination	NCT00002234 ↗	Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients	Completed	Glaxo Wellcome	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.
New Combination	NCT00002234 ↗	Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients	Completed	Gilead Sciences	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.

All Clinical Trials for DIDANOSINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000625 ↗	A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3	Completed	Bristol-Myers Squibb	Phase 2	1969-12-31	To determine the efficacy and safety of zidovudine ( AZT ) versus didanosine ( ddI ), AZT plus ddI, and AZT plus zalcitabine ( ddC ) in preventing disease progression in HIV-infected patients with CD4 counts of 200-500 cells/mm3.
NCT00000625 ↗	A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3	Completed	Glaxo Wellcome	Phase 2	1969-12-31	To determine the efficacy and safety of zidovudine ( AZT ) versus didanosine ( ddI ), AZT plus ddI, and AZT plus zalcitabine ( ddC ) in preventing disease progression in HIV-infected patients with CD4 counts of 200-500 cells/mm3.
NCT00000625 ↗	A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To determine the efficacy and safety of zidovudine ( AZT ) versus didanosine ( ddI ), AZT plus ddI, and AZT plus zalcitabine ( ddC ) in preventing disease progression in HIV-infected patients with CD4 counts of 200-500 cells/mm3.
NCT00000637 ↗	A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children	Completed	Bristol-Myers Squibb	Phase 3	1969-12-31	To compare the effectiveness of treatment with zidovudine (AZT) compared to didanosine (ddI) and compared to the combination of AZT and ddI as determined by survival and disease progression. To compare the relative safety and tolerance of AZT versus ddI versus AZT plus ddI in symptomatic HIV infected children; to compare the virological and immunological parameters in the three treatment groups. AZT has been shown to delay the progression of AIDS in HIV infected individuals. However, bone marrow toxicity is a frequent adverse effect. Also, HIV resistance to AZT sometimes occurs in patients who initially respond to treatment, but later have progression of the disease. Thus, new drug treatments are needed. Studies of ddI in adults and children indicate some effectiveness of the drug. A direct comparison of AZT and ddI treatment in children has not been made. Combination antiviral treatment (AZT plus ddI) may give added therapeutic benefit to children.

Clinical Trial Conditions for DIDANOSINE

Condition Name

Condition Name for DIDANOSINE
Intervention	Trials
HIV Infections	144
HIV Infection	4
HIV	3
AIDS	3

Condition MeSH

Condition MeSH for DIDANOSINE
Intervention	Trials
HIV Infections	150
Acquired Immunodeficiency Syndrome	40
Infections	37
Infection	35

Clinical Trial Locations for DIDANOSINE

Trials by Country

Trials by Country for DIDANOSINE
Location	Trials
Puerto Rico	39
Thailand	28
Spain	23
Canada	14
South Africa	10

Trials by US State

Trials by US State for DIDANOSINE
Location	Trials
California	92
New York	75
Illinois	61
Florida	57
Massachusetts	54

Clinical Trial Progress for DIDANOSINE

Clinical Trial Phase

Clinical Trial Phase for DIDANOSINE
Clinical Trial Phase	Trials
Phase 4	13
Phase 3	19
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for DIDANOSINE
Clinical Trial Phase	Trials
Completed	136
Unknown status	8
Terminated	6

Clinical Trial Sponsors for DIDANOSINE

Sponsor Name

Sponsor Name for DIDANOSINE
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	81
Bristol-Myers Squibb	45
Glaxo Wellcome	18

Sponsor Type

Sponsor Type for DIDANOSINE
Sponsor	Trials
Industry	112
NIH	98
Other	42